CollabRx Launches Expansion of Its Genetic Variation Annotation Service to Support Copy Number Variation (CNV) Data

CollabRx, Inc. CLRX, launched its expanded Genetic Variant Annotation™ (GVA™) Service that now supports the interpretation of copy number variation (CNV) data in cancer, resulting in a single, user-friendly report that contains clinically relevant and dynamically updated information that has been used toward cancer treatment planning and support of clinical research.

San Francisco, California (PRWEB) September 11, 2014

CollabRx, Inc. CLRX, a leading provider of software and IT systems that support clinical decision-making in oncology, launched its expanded Genetic Variant Annotation™ (GVA™) Service that now supports the interpretation of copy number variation (CNV) data in cancer, resulting in a single, user-friendly report that contains clinically relevant and dynamically updated information that has been used toward cancer treatment planning and support of clinical research. CNVs, which involve both duplications and deletions of the human genome, have been increasingly recognized as playing a role in certain diseases, including cancer.

The expansion of the GVA Service, a widely used, highly scalable, fully automated, cloud-based, electronic decision support system that provides a turnkey analysis of many types of genetic alterations in cancer, comes from the Company's previously announced partnership with Affymetrix AFFX. The objective of this partnership is to enable translational and clinical research laboratories worldwide to have broad access to a powerful informatics solution capable of pairing large-scale tumor mutation data from next-generation sequencing technologies with tumor CNV data from Affymetrix and other platforms. With this expansion, the GVA Service can now accept and process both somatic mutation data and gene CNV data from the same tumor and return an integrated interpretive report.

“Recent data have established the relevance of tumor copy number data as an important consideration in informing a cancer treatment plan, including available clinical trials, based on tumor genetic profiles,” said Gavin Gordon, CollabRx's Vice President of Business Development and Strategic Alliances. “As a result, leading translational and clinical research laboratories are beginning to include CNV data in their integrated cancer genomic assessments. Through the GVA Service, CollabRx can provide these laboratories with easily accessible and authoritative informatics solutions to integrate copy number information with somatic mutation information in an automated and standardized way. This provides additional data for decision-making based on the results of comprehensive genetic profiling.”

The GVA Service accepts tumor genetic data from any source or platform and pairs it with information contained in a knowledge base that includes the impact of specific genetic profiles. The CollabRx knowledge base is supported by a proprietary technology platform and expert system that leverages a large and growing network of more than 75 thought-leaders and clinical practitioners in the United States and Europe who are working together to develop new tools for informing decision-making in oncology. The GVA Service is offered to customers in a combination Software as a Service (SaaS) and subscription business model.

Thomas Mika, Chairman, President and CEO of CollabRx, said, “The significant expansion of our database, which not only optimizes our GVA Service with Affymetrix platforms but also with all platforms that are used for analyzing CNV, has paved the way for new commercial and clinical research clients. We are extremely pleased to have partnered with Affymetrix on this enhancement.”

About CollabRx
CollabRx, Inc. (CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.

CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx's anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx's plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/09/prweb12157932.htm